Annovation BioPharma, Inc. — Form D/A
Annovation BioPharma, Inc. of Cambridge, MA, a company, filed a Form D amendment with the SEC on 2014-04-17. The offering totals $11.0M, of which $8.0M was reported sold. Industry: Pharmaceuticals.
Offering
- Filed: 2014-04-17
- Form: D/A
- Accession: 0001517294-14-000001
- Industry: Pharmaceuticals
- Exemptions: 06b
- Total offering: $11.0M
- Amount sold: $8.0M
- Remaining: $3.0M
- Investors: 10
- Date of first sale: 2012-07-23
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-181765
Issuer
- Name: Annovation BioPharma, Inc.
- CIK: 0001517294
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2009
- Address: c/o Atlas Venture, Cambridge, MA, 02141
- Phone: 617-588-2600
Officers, directors & promoters (9)
| Name | Role | Location |
|---|
| Carl Berke | Director | Cambridge, MA |
| Jason Campagna | Director | Cambridge, MA |
| Jean-Francois Formela | Director | Cambridge, MA |
| David Grayzel | Director | Cambridge, MA |
| Ankit Mahadevia | Director | Cambridge, MA |
| Carl Berke | Executive Officer | Cambridge, MA |
| David Grayzel | Executive Officer | Cambridge, MA |
| Douglas Raines | Director | Cambridge, MA |
| Nicholas Barker | Director | Cambridge, MA |
Other filings by this issuer (2)
More